ai
Immunai Expands Oncology Collaboration With AstraZeneca
The New York-headquartered, Israeli-founded AI biotech company Immunai has expanded its multi-year collaboration with AstraZeneca in oncology clinical development. Under the agreement, Immunai is eligible to receive up to $37.5 million over 2026 and 2027. The companies will continue using Immunai’s AMICA-OS AI platform to support drug development through 2027.
May 7, 3:33 PM·1m read1 source
JE
forbes.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The company said in a statement that it is eligible to receive up to $37.5 million over 2026 and 2027 under the expanded agreement. The expanded agreement extends and broadens the companies’ multi-year collaboration in oncology through 2027. AstraZeneca will continue using Immunai’s AMICA-OS AI operating system.
The platform combines clinical immunology data at single-cell resolution with advanced AI models of the immune system. The AMICA-OS platform is designed to support oncology drug development by generating insights for biomarker discovery, patient stratification, mechanism-of-action analysis, and dose optimization, the company said.
This marks the third expansion of the collaboration between the two companies.
It follows a 2024 agreement to apply Immunai’s platform across AstraZeneca oncology clinical programs and a 2025 agreement expanding the collaboration into inflammatory bowel disease. The company uses single-cell genomics and machine learning to study the human immune system and support the development of therapeutics.
Its AMICA-OS platform integrates large-scale immune data with AI models to generate insights that can be used in drug development. Immunai is headquartered in New York City and has offices in Tel Aviv, Prague, and Zurich. The company said it has more than 170 experts and has raised close to $270 million to date.
